Related Experiment Video
Updated: May 22, 2026
06:33
Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Published on: November 10, 2023
[Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)]
Kisato Nosaka1, Tatsuya Kawaguchi
1Cancer Center, Kumamoto University Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 25, 2012
Summary
Hematopoietic malignancies like leukemia require monitoring for minimal residual disease (MRD) to assess treatment effectiveness and detect relapse. Immunophenotypes, fusion genes, and serum markers aid in diagnosis and tracking disease progression.
Area of Science:
- Hematology and Oncology
- Molecular Diagnostics
- Biomarker Discovery
Context:
- Hematopoietic malignancies (leukemia, lymphoma, multiple myeloma) are currently classified and prognosed using morphologic, cytogenetic, and molecular features.
- Advances in molecular targeted therapy and hematopoietic stem cell transplantation necessitate precise monitoring of minimal residual disease (MRD) for optimal treatment response evaluation and early relapse detection.
Purpose:
- To highlight the clinical utility of immunophenotypes and chimeric fusion genes as biomarkers for classifying hematopoietic malignancies and monitoring MRD.
- To emphasize the role of serum markers in tracking disease progression in these cancers.
Summary:
- Immunophenotypes and chimeric fusion genes are valuable biomarkers for subtyping hematopoietic malignancies at diagnosis and for monitoring MRD.
- Serum markers such as LDH, soluble IL-2 receptor, M-protein, and free light chains are clinically useful for monitoring tumor burden and disease progression.
Impact:
- Improved diagnostic accuracy and subtyping of hematopoietic malignancies.
- Enhanced monitoring of treatment efficacy and early detection of relapse through MRD assessment.
- Facilitation of personalized treatment strategies based on robust biomarker analysis.
Related Concept Videos
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:21Hematopoiesis
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
01:19Multipotency of Hematopoietic Stem Cells
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
01:20Overview of Hematopoiesis
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...